Dr Malcolm AbelTo Be Presented at SEALSB Atlanta 2008
The FDA has a policy of requiring that the first filer of an approved ANDA be sued to preserve its statutory exclusivity when the NDA holder seeks to remove the patent from the Orange Book. This paper discusses whether or not this policy is a valid one.
|